Insider Selling: Liquidia Technologies (NASDAQ:LQDA) Insider Sells 451 Shares of Stock

Key Points

• Jason Adair, an insider at Liquidia Technologies, sold 451 shares on September 2nd for a total of $13,101.55, reducing his ownership to 172,980 shares valued at approximately $5 million.
• Liquidia Technologies reported a quarterly earnings loss of ($0.49) per share, which was worse than the consensus estimate, despite a revenue increase of 141.5% year-over-year.
• Analysts have given Liquidia Technologies a consensus rating of "Buy", with price target estimates ranging from $23.00 to $41.00 per share.

Liquidia Technologies, Inc. (NASDAQ:LQDA - Get Free Report) insider Jason Adair sold 451 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $29.05, for a total transaction of $13,101.55. Following the sale, the insider directly owned 172,980 shares in the company, valued at approximately $5,025,069. The trade was a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Jason Adair also recently made the following trade(s):

• On Tuesday, September 2nd, Jason Adair sold 451 shares of Liquidia Technologies stock. The stock was sold at an average price of $29.05, for a total transaction of $13,101.55.
• On Thursday, August 28th, Jason Adair sold 26,057 shares of Liquidia Technologies stock. The stock was sold at an average price of $27.86, for a total transaction of $725,948.02.
• On Monday, July 28th, Jason Adair sold 454 shares of Liquidia Technologies stock. The stock was sold at an average price of $19.54, for a total transaction of $8,871.16.
• On Monday, July 14th, Jason Adair sold 2,576 shares of Liquidia Technologies stock. The stock was sold at an average price of $14.28, for a total transaction of $36,785.28.

Liquidia Technologies Price Performance

Shares of LQDA traded up $0.90 during mid-day trading on Tuesday, hitting $28.58. 3,973,236 shares of the company were exchanged, compared to its average volume of 1,817,921. Liquidia Technologies, Inc. has a 1-year low of $8.75 and a 1-year high of $29.28. The company has a debt-to-equity ratio of 9.84, a quick ratio of 2.41 and a current ratio of 2.49. The company has a 50 day moving average of $19.18 and a 200-day moving average of $16.44. The stock has a market cap of $2.46 billion, a price-to-earnings ratio of -16.81 and a beta of 0.22.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.06). Liquidia Technologies had a negative return on equity of 232.96% and a negative net margin of 732.17%.The company had revenue of $8.84 million for the quarter, compared to analyst estimates of $3.90 million. The business's revenue was up 141.5% on a year-over-year basis. Analysts expect that Liquidia Technologies, Inc. will post -1.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on LQDA. Needham & Company LLC upped their price target on shares of Liquidia Technologies from $32.00 to $36.00 and gave the stock a "buy" rating in a research report on Tuesday, August 12th. Bank of America cut their price objective on shares of Liquidia Technologies from $25.00 to $23.00 and set a "buy" rating for the company in a report on Wednesday, June 11th. Scotiabank increased their price objective on shares of Liquidia Technologies from $36.00 to $37.00 and gave the company a "sector outperform" rating in a report on Wednesday, May 28th. BTIG Research reiterated a "buy" rating on shares of Liquidia Technologies in a report on Tuesday, May 27th. Finally, Raymond James Financial increased their price objective on shares of Liquidia Technologies from $33.00 to $41.00 and gave the company a "strong-buy" rating in a report on Wednesday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $32.11.

Institutional Trading of Liquidia Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Ballentine Partners LLC increased its holdings in shares of Liquidia Technologies by 10.2% during the 2nd quarter. Ballentine Partners LLC now owns 12,139 shares of the company's stock worth $151,000 after buying an additional 1,119 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Liquidia Technologies by 65.6% during the 1st quarter. GAMMA Investing LLC now owns 2,961 shares of the company's stock worth $44,000 after buying an additional 1,173 shares during the last quarter. Steward Partners Investment Advisory LLC increased its holdings in shares of Liquidia Technologies by 24.0% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company's stock worth $77,000 after buying an additional 1,200 shares during the last quarter. Cetera Investment Advisers boosted its position in shares of Liquidia Technologies by 4.3% during the 4th quarter. Cetera Investment Advisers now owns 31,243 shares of the company's stock worth $367,000 after purchasing an additional 1,277 shares during the period. Finally, Valmark Advisers Inc. boosted its position in shares of Liquidia Technologies by 7.4% during the 1st quarter. Valmark Advisers Inc. now owns 18,641 shares of the company's stock worth $275,000 after purchasing an additional 1,283 shares during the period. Institutional investors and hedge funds own 64.54% of the company's stock.

Liquidia Technologies Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.